3 New Strong Buy Ratings from Top-Rated Analysts: 05/01/2026

Using our popular Zen Ratings + Top Analysts feature, we sourced 3 stocks with excellent quant ratings and Smart Money support:

• Gilead Sciences (GILD) — HIV breakthrough and Arcellx deal fuel upside
• Amneal Pharmaceuticals (AMRX) — Biosimilars boom drives 339% EPS growth
• Levi Strauss (LEVI) — DTC transformation delivers double-digit revenue growth

P.S. Get more alerts like this daily … Try WallStreetZen Premium.

A note from our sponsors...

1. Amneal Pharmaceuticals Inc (NASDAQ: AMRX)

Amneal Pharmaceuticals is emerging as a powerhouse in biosimilars scale opportunities, with strong preliminary Q1 results and a game-changing Kashiv BioSciences acquisition igniting analyst enthusiasm. Now ranked #1 in the Pharmaceutical industry, this generic and specialty drug manufacturer is positioned for serious upside.

Zen Rating: Strong Buy (A) — see full analysis

Recent Price: $12.79 — get current quote

Max 1-year forecast: $19.00

Why we're watching:

• Analyst support: AMRX enjoys unanimous bullish sentiment with 4 out of 4 analysts rating the stock Strong Buy. See the ratings
• For example, UBS researcher Ashwani Verma (a top 14% rated analyst) recently initiated coverage with a Strong Buy rating and $19 price target, representing 49% upside potential, highlighting the company's biosimilar pipeline and anticipated 2026-2027 upside from biosimilars scale.
• AMRX also enjoys strong support from our Editor-in-Chief Steve Reitmeister, whose recent video showcases the stock’s strengths. Watch it here
• Great growth: The company's earnings growth of 128.71% significantly outpaces both the industry average of 19.82% and market average of 72.91%, with EPS forecasted to grow from $0.23 to $1.01 over the next year—a remarkable 339% increase.
• Industry ranking context: AMRX is currently the #1 highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of A.
• Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — AMRX is in the top echelon of stocks we track.
• Component Grades: Outstanding performance in Growth (A) and Sentiment (A) grades, reflecting strong analyst conviction and impressive earnings expansion potential, complemented by a solid B grade in Value. (See all 7 Zen Component Grades here)

2. Levi Strauss & Co (NYSE: LEVI)

Levi Strauss, the iconic denim brand, is pulling off a stunning transformation into a DTC-first lifestyle powerhouse — and the numbers prove it. Q1 2026 direct-to-consumer revenues surged 16% year-over-year and now account for more than half of total revenue, with heritage demand and sharp operational focus fueling the fastest, most consistent growth in the company's history.

Zen Rating: Strong Buy (A) — see full analysis

Recent Price: $21.86 — get current quote

Max 1-year forecast: $34.00

Why we're watching:

• Analyst support: Strong consensus with 2 Strong Buy ratings and 3 Buy ratings from 5 analysts covering the stock, with zero Hold, Sell, or Strong Sell ratings. See the ratings
• For example, UBS researcher Jay Sole (a top 6% rated analyst) recently raised his price target to $34 following Q1 earnings, noting the company is "undertaking a transformation into a global, multi-channel, lifestyle brand for both men and women" that will support mid-single-digit revenue growth with mid-teens margins over time.
• Recent catalysts: Q1 2026 earnings showcased exceptional execution with EPS of $0.42 beating estimates by 13.51% and revenue of $1.74B exceeding expectations by 5.45%, both growing double-digits year-over-year as the DTC transformation gains momentum.
• Industry ranking context: LEVI is currently the #1 highest-rated stock in the Apparel Manufacturing industry, which has an Industry Rating of A.
• Zen Rating highlights: As an A or Strong Buy rated stock, LEVI ranks in the top 5% of stocks we track based on a 115-factor evaluation of factors that have historically driven long-term stock growth. 
• Component Grades: Well-rounded performance with A grade in Sentiment reflecting strong analyst confidence, B grades in Value, Growth, Safety, and Financials, demonstrating solid fundamentals across the board. (See all 7 Zen Component Grades here)

3. Gilead Sciences Inc (NASDAQ: GILD)

Gilead Sciences is riding powerful momentum after the FDA granted priority review to its once-daily HIV treatment combining bictegravir and lenacapavir, while its newly completed Arcellx acquisition sets the stage for anito-cel's commercial launch. Ranked #1 in the General Drug Manufacturer industry, this biopharmaceutical leader continues delivering standout execution across its HIV and oncology franchises.

Zen Rating: Strong Buy (A) — see full analysis

Recent Price: $128.00 — get current quote

Max 1-year forecast: $180.00

Why we're watching:

• Analyst support: Strong Wall Street backing with 9 Strong Buy ratings, 2 Buy ratings, and 2 Hold ratings out of 13 analysts covering the stock. See the ratings
• For example, Needham researcher Joseph Stringer (a top 1% rated analyst) recently reiterated his Buy rating with a $170 price target following the company's strategic portfolio expansion. His target suggests over 30% potential upside in the coming year. 
• Industry ranking context: GILD is currently the #1 highest-rated stock in the General Drug Manufacturer industry, which has an Industry Rating of A.
• Zen Rating highlights: GILD earns an overall Zen Rating of A, putting it in a class of stocks that have historically returned over 30% annually to investors. 
• Component Grades: The stock excels with A grades in Value and Financials, indicating strong fundamentals and attractive valuation metrics, while maintaining a B grade in Safety and Artificial Intelligence exposure. (See all 7 Zen Component Grades here)

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.